13876 Achieving a PASI 50 at 2 weeks was associated with better long-term clinical outcomes and low discontinuation: A subgroup analysis of a phase 3 trial of ixekizumab and etanercept in moderate to severe psoriasis
Rosmarin, David, Shrom, David, Burge, Russel, See, Kyoungah, McKean-Matthews, Missy, Ridenour, TerriVolume:
83
Journal:
Journal of the American Academy of Dermatology
DOI:
10.1016/j.jaad.2020.06.588
Date:
December, 2020
File:
PDF, 243 KB
2020